Paper Details

  1. Home
  2. Paper Details

Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer.

Author: AlbertssonPer, BraideKarin, EdgrenMaliha, JellvertAsa, KindblomJon, LennernäsBo, LissbrantIngela Franck, OlvenmarkAnn-Marie Ekelund, OvferholmElisabeth

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This pilot study evaluated the efficacy and safety of a chemo-hormonal treatment regimen called KEES in patients with chemonaive castration-resistant prostate cancer (CRPC). The study found that KEES resulted in a clear reduction in PSA with limited toxicity.
Paper Details　
Original Abstract of the Article :
Prostate cancer (PC) was previously believed to be a chemoresistant disease. In recent years taxane-based chemotherapy has been shown to prolong survival in patients with castration-resistant prostate cancer (CRPC). It remains to be shown, however, which type of chemotherapy provides the most benefi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440841/

データ提供：米国国立医学図書館（NLM）

A New Path in Prostate Cancer Treatment: A Camel's Journey Through Metronomic Chemotherapy

The field of oncology is continuously searching for effective and less toxic treatment options for prostate cancer. This research investigates the potential of metronomic chemotherapy, a low-dose, frequent chemotherapy regimen, as a treatment for castration-resistant prostate cancer (CRPC). The researchers conducted a pilot study to evaluate the efficacy and safety of a specific metronomic chemo-hormonal regimen called KEES in patients with CRPC.

A New Oasis in the Desert of Prostate Cancer: A Camel's Perspective

The study found that the KEES regimen significantly reduced prostate-specific antigen (PSA) levels in a majority of patients with CRPC, indicating a potential benefit in treating this challenging disease. The study also found that the KEES regimen was generally well-tolerated, with manageable side effects. These promising results warrant further investigation in larger clinical trials.

Navigating the Desert of Prostate Cancer Treatment: A Camel's Advice

If you're facing a diagnosis of castration-resistant prostate cancer, it's essential to consult with a healthcare professional to discuss all available treatment options, including metronomic chemotherapy. While the KEES regimen shows promise, further research is needed to determine its long-term effectiveness and optimal use in clinical practice. Remember, the journey through prostate cancer treatment is often challenging, but there are resources and support available to help you navigate this complex landscape.

Dr.Camel's Conclusion

This research provides exciting evidence for the potential of metronomic chemotherapy as a less toxic and effective treatment option for castration-resistant prostate cancer. It underscores the importance of exploring novel treatment strategies in oncology to improve patient outcomes and minimize the burden of disease.

Date :
  1. Date Completed n.d.
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

22977543

DOI: Digital Object Identifier

PMC3440841

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.